drugset
drugset / Trial / NCT01089608

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

NCT01089608 ↗

Phase 2 Completed 93 enrolled Laboratoires Thea Keyrus Biopharma · collabVEEDA · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to demonstrate the efficacy of T1225 eye drops versus placebo eye drops on the global ocular discomfort (VAS).

Timeline

Start
2010-03
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 1.5 % Other

Indications

blepharitis